Hints and tips:
Related Special Reports
...said Jonas Andrulis, founder and chief executive of Aleph Alpha....
...Schwarz Group, which controls Lidl and is building out a new IT division, is co-leading the deal alongside an AI hub based in the south-west German city of Heilbronn that was jointly set up by a foundation...
...Northern Ireland is “well placed both in terms of serving the international market but actually building the innovation at home”, said Peter Keeling, Diaceutics co-founder....
...Swiss company Roche acquired obesity drug developer Carmot Therapeutics for $3.1bn last month, while AstraZeneca signed a $2bn licensing agreement with Eccogene, a Chinese maker of an oral obesity drug in...
...US biotech Viking Therapeutics’ shares more than doubled after trial data for the company’s weight-loss drug outperformed existing treatments from drugmakers Novo Nordisk and Eli Lilly....
...In December, BMS announced a $14bn deal for Karuna Therapeutics which owns the schizophrenia drug KarXT....
...According to preliminary data, it cut body weight by 14.5 per cent after 12 weeks, a similar result to the weekly injection being trialled by Viking Therapeutics....
...therapies based on Crispr gene-editing globally is “unrealistic” and the sector needs heavy investment to make the technology, which could transform treatment of diseases, accessible to all, according to its co-discoverer...
...It was closely connected with Silicon Valley royalty: Anne Wojcicki, the company’s co-founder and chief executive, received early backing from Sergey Brin, the co-founder of Google whom she went on to marry...
...The two biotech companies at the forefront of developing the therapy are CRISPR Therapeutics and Vertex Pharmaceuticals....
...Novo Nordisk purchased Dicerna Pharmaceuticals, a company focused in RNA-based therapeutics, for $3.3bn in 2021....
...Charpentier formed Crispr Therapeutics, a Nasdaq-listed company, in 2013 to boost the development of gene editing to treat diseases....
...Click here for the answers James Walton is co-host of “The Booker Prize Podcast”...
...Orchard Therapeutics’ Lenmeldy this week became the first US approved medicine for metachromatic leukodystrophy (MLD), a fatal genetic disorder affecting an average of 40 new-born babies a year in the US...
...These particularly benefit from co-location with strong academic centres....
...Byron Callan, managing director of research group Capital Alpha Partners, said: “Given the travails of the company in recent years, it’s not clear to us how deep a bench there is in terms of people internally...
...Beijing is also diversifying its import sources and has signed more than 100 agricultural co-operation agreements with countries involved in the Belt and Road Initiative, its global infrastructure scheme...
...“What is most important is that it kills antibiotic-resistant strains in animals,” said Yury Polikanov, co-author of the research and an associate professor of biological sciences at the University of Illinois...
...“I’ve never seen anything like this, the chaos,” said Byron Callan, managing director of research group Capital Alpha Partners. “It’s really a very chaotic environment in Washington right now.”...
...Peter Soelkner, managing director of Vetter, which has the capacity to produce at least 210mn injectable doses a year, said contract manufacturers were “witnessing increased demand in specific therapeutic...
...However, Rokos Capital Management, run by former Brevan Howard co-founder Chris Rokos, ended 2023 up 8.8 per cent....
...Alice, an alpha-female financier, fluctuates between icy standoffishness and warm tenderness; Jack, an awkward lab scientist, seems caught between fear and exhilaration....
...By day, they can choose from hypnotherapy, therapeutic breathwork and EFT (or “tapping”, said to activate meridional energy to process negative emotion)....
...Brevan Howard’s flagship fund was down 2.1 per cent while its Alpha Strategies fund was up 2.4 per cent, according to people who have seen the figures....
...Companies such as Microbiotica, a Cambridge-based 2016 spinout from the Wellcome Sanger Institute, are working to develop therapeutics based on bugs in the digestive system....
International Edition